An exclusive interview with Dr. Mehmood Khan, founding CEO of Saudi Arabia's HEVOLUTION Foundation

The 966

The 966 speaks with Dr. Mehmood Khan, CEO of Saudi Arabia’s Hevolution Foundation, a global non-profit revolutionizing the healthspan field launched by Royal Decree and chaired by HRH the Crown Prince Mohammed bin Salman. Dr. Khan shares his journey, Hevolution’s vision and insights into how he is working to build the organization’s operations from the ground up. The 966’s conversation with Dr. Khan takes place ahead of Hevolution’s inaugural Global Healthspan Summit on Nov. 29-30 in Riyadh, Saudi Arabia. The two-day event at the Four Seasons Hotel promises to serve as a seismic shift in how the world perceives and acts, catalyzing the discussion from lifespan to healthspan.

Dr. Khan's interview begins at the 7:55 mark.

#Hevolution is headquartered in Riyadh with additional international hubs to support the expansion and execute the global mission. Its vision is to expand healthy human lifespan for the benefit of all humanity. Hevolution Foundation aims to be positioned as a global leader, catalyst, partner, and convener, to increase the number of scientists entering the field, to increase the investable opportunities in the field of aging, to help shape the regulatory and government environment.

Dr. Khan also currently serves as the Executive Chairman of Life Biosciences Inc. where he joined the company in April 2019 as the Chief Executive Officer and Board Member. Life Biosciences was founded to advance scientific research and develop innovative new therapies to improve and extend healthy lives for everyone.

Dr. Khan previously served as Vice Chairman and Chief Scientific Officer of Global Research and Development at PepsiCo, a Fortune 50 company employing upwards of 250,000 employees across 22 brands. At PepsiCo, Dr. Khan played a pivotal role in the company’s global R&D efforts to create breakthrough innovations in food, beverages, and nutrition, including the incorporation of healthier and more nutritious offerings across its portfolio. Dr. Khan also oversaw PepsiCo's global sustainability initiatives based on the belief that success in business is inextricably linked to the sustainability of the world we share. Prior to joining PepsiCo, Dr. Khan served as President of Global R&D at Takeda Pharmaceuticals, leading the global efforts of one of the largest pharmaceutical companies in the world by revenue.

Before moving into industry, Dr. Khan had a distinguished medical career as a faculty member in endocrinology at the Mayo Clinic and Mayo Medical School where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit. He also spent nine years leading programs in diabetes, endocrinology, metabolism and nutrition in Minneapolis, MN.

Dr. Khan is currently a member of the Board of Directors of Reckitt Benckiser.